BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 25668429)

  • 1. Evolution of p53 transactivation specificity through the lens of a yeast-based functional assay.
    Lion M; Raimondi I; Donati S; Jousson O; Ciribilli Y; Inga A
    PLoS One; 2015; 10(2):e0116177. PubMed ID: 25668429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional evolution of the p53 regulatory network through its target response elements.
    Jegga AG; Inga A; Menendez D; Aronow BJ; Resnick MA
    Proc Natl Acad Sci U S A; 2008 Jan; 105(3):944-9. PubMed ID: 18187580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noncanonical DNA motifs as transactivation targets by wild type and mutant p53.
    Jordan JJ; Menendez D; Inga A; Noureddine M; Bell DA; Resnick MA
    PLoS Genet; 2008 Jun; 4(6):e1000104. PubMed ID: 18714371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
    Inga A; Resnick MA
    Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functionally distinct polymorphic sequences in the human genome that are targets for p53 transactivation.
    Tomso DJ; Inga A; Menendez D; Pittman GS; Campbell MR; Storici F; Bell DA; Resnick MA
    Proc Natl Acad Sci U S A; 2005 May; 102(18):6431-6. PubMed ID: 15843459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity.
    Resnick MA; Inga A
    Proc Natl Acad Sci U S A; 2003 Aug; 100(17):9934-9. PubMed ID: 12909720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence.
    Inga A; Storici F; Darden TA; Resnick MA
    Mol Cell Biol; 2002 Dec; 22(24):8612-25. PubMed ID: 12446780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Divergent evolution of human p53 binding sites: cell cycle versus apoptosis.
    Horvath MM; Wang X; Resnick MA; Bell DA
    PLoS Genet; 2007 Jul; 3(7):e127. PubMed ID: 17677004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactions of chromatin context, binding site sequence content, and sequence evolution in stress-induced p53 occupancy and transactivation.
    Su D; Wang X; Campbell MR; Song L; Safi A; Crawford GE; Bell DA
    PLoS Genet; 2015 Jan; 11(1):e1004885. PubMed ID: 25569532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potentiating the p53 network.
    Menendez D; Inga A; Resnick MA
    Discov Med; 2010 Jul; 10(50):94-100. PubMed ID: 20670604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay.
    Di Como CJ; Prives C
    Oncogene; 1998 May; 16(19):2527-39. PubMed ID: 9627118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptional properties of feline p53 and its tumour-associated mutants: a yeast-based approach.
    Cardellino U; Ciribilli Y; Andreotti V; Modesto P; Menichini P; Fronza G; Pellegrino C; Inga A
    Mutagenesis; 2007 Nov; 22(6):417-23. PubMed ID: 17947339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-genome cartography of p53 response elements ranked on transactivation potential.
    Tebaldi T; Zaccara S; Alessandrini F; Bisio A; Ciribilli Y; Inga A
    BMC Genomics; 2015 Jun; 16(1):464. PubMed ID: 26081755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay.
    Inga A; Monti P; Fronza G; Darden T; Resnick MA
    Oncogene; 2001 Jan; 20(4):501-13. PubMed ID: 11313981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative Analysis of NF-κB Transactivation Specificity Using a Yeast-Based Functional Assay.
    Sharma V; Jordan JJ; Ciribilli Y; Resnick MA; Bisio A; Inga A
    PLoS One; 2015; 10(7):e0130170. PubMed ID: 26147604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The structure formed by inverted repeats in p53 response elements determines the transactivation activity of p53 protein.
    Brázda V; Čechová J; Battistin M; Coufal J; Jagelská EB; Raimondi I; Inga A
    Biochem Biophys Res Commun; 2017 Jan; 483(1):516-521. PubMed ID: 28007599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of p53-target genes in Danio rerio.
    Mandriani B; Castellana S; Rinaldi C; Manzoni M; Venuto S; Rodriguez-Aznar E; Galceran J; Nieto MA; Borsani G; Monti E; Mazza T; Merla G; Micale L
    Sci Rep; 2016 Sep; 6():32474. PubMed ID: 27581768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human transcription factors in yeast: the fruitful examples of P53 and NF-кB.
    Sharma V; Monti P; Fronza G; Inga A
    FEMS Yeast Res; 2016 Nov; 16(7):. PubMed ID: 27683095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 transactivation and the impact of mutations, cofactors and small molecules using a simplified yeast-based screening system.
    Andreotti V; Ciribilli Y; Monti P; Bisio A; Lion M; Jordan J; Fronza G; Menichini P; Resnick MA; Inga A
    PLoS One; 2011; 6(6):e20643. PubMed ID: 21674059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
    Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G
    Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.